CymaBay Announces Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
CymaBay Therapeutics (CBAY) Prices 8M Common Stock Offering at $12.50/Share
March 6, 2019 8:04 AM ESTCymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of... More
CymaBay Therapeutics (CBAY) Offering is Said to Price at $12.50/Share - Bloomberg
March 6, 2019 6:56 AM ESTCymaBay Therapeutics (NASDAQ: CBAY) Offering is Said to Price at $12.50/Share - Bloomberg
